PT2804878T - Anticorpos anti-cxcr3 - Google Patents

Anticorpos anti-cxcr3

Info

Publication number
PT2804878T
PT2804878T PT13702548T PT13702548T PT2804878T PT 2804878 T PT2804878 T PT 2804878T PT 13702548 T PT13702548 T PT 13702548T PT 13702548 T PT13702548 T PT 13702548T PT 2804878 T PT2804878 T PT 2804878T
Authority
PT
Portugal
Prior art keywords
cxcr3 antibodies
cxcr3
antibodies
Prior art date
Application number
PT13702548T
Other languages
English (en)
Inventor
Youd Michele
Tedstone Jennifer
Lodie Tracey
B Carter Karen
D Connors Timothy
Robert Pinckney Jason
Masterjohn Elizabeth
Chu Ruiyin
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of PT2804878T publication Critical patent/PT2804878T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
PT13702548T 2012-01-20 2013-01-18 Anticorpos anti-cxcr3 PT2804878T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261588936P 2012-01-20 2012-01-20

Publications (1)

Publication Number Publication Date
PT2804878T true PT2804878T (pt) 2018-11-29

Family

ID=47633576

Family Applications (1)

Application Number Title Priority Date Filing Date
PT13702548T PT2804878T (pt) 2012-01-20 2013-01-18 Anticorpos anti-cxcr3

Country Status (27)

Country Link
US (4) US8865870B2 (pt)
EP (1) EP2804878B1 (pt)
JP (3) JP6352812B6 (pt)
KR (2) KR20200014441A (pt)
CN (1) CN104507967B (pt)
AR (1) AR090056A1 (pt)
AU (1) AU2013209492B2 (pt)
BR (1) BR112014017814A8 (pt)
CA (1) CA2862222A1 (pt)
CY (1) CY1121335T1 (pt)
DK (1) DK2804878T3 (pt)
ES (1) ES2698606T3 (pt)
HK (1) HK1208684A1 (pt)
HR (1) HRP20181874T1 (pt)
HU (1) HUE041900T2 (pt)
IL (2) IL233694A0 (pt)
LT (1) LT2804878T (pt)
MX (1) MX359854B (pt)
PL (1) PL2804878T3 (pt)
PT (1) PT2804878T (pt)
RS (1) RS58141B1 (pt)
RU (1) RU2663141C2 (pt)
SG (2) SG11201406762QA (pt)
SI (1) SI2804878T1 (pt)
TW (1) TWI596112B (pt)
UY (1) UY34582A (pt)
WO (1) WO2013109974A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
AU2015305894A1 (en) 2014-08-22 2017-04-06 Sorrento Therapeutics, Inc. Antigen binding proteins that bind CXCR3
EP3368575A2 (en) 2015-10-29 2018-09-05 Alector LLC Anti-siglec-9 antibodies and methods of use thereof
US11104724B2 (en) 2016-05-23 2021-08-31 New York University Compositions and methods for antibodies targeting staphylococcal leukotoxins
US20180244787A1 (en) 2016-12-22 2018-08-30 Sanofi Anti-human cxcr3 antibodies for treatment of vitiligo
WO2018119299A1 (en) 2016-12-22 2018-06-28 Sanofi Humanized cxcr3 antibodies with depleting activity and methods of use thereof
KR20190095942A (ko) * 2016-12-22 2019-08-16 사노피 백반증의 치료를 위한 항-인간 cxcr3 항체
CA3091311A1 (en) * 2018-02-16 2019-08-22 Inserm (Institut National De La Sante Et De La Recherche Medicale) Use of antagonists of cxcr3b for treating vitiligo
WO2020102422A1 (en) * 2018-11-14 2020-05-22 Arch Oncology, Inc. THERAPEUTIC SIRPα ANTIBODIES
DK3872091T3 (da) 2020-02-26 2023-09-11 Vir Biotechnology Inc Antistoffer mod sars-cov-2
CN116234572A (zh) * 2020-04-30 2023-06-06 安驰肿瘤公司 治疗性SIRPα抗体
JP2024505600A (ja) 2021-02-03 2024-02-06 モーツァルト セラピューティクス， インコーポレイテッド 結合剤およびそれを使用する方法
AU2022229356A1 (en) * 2021-03-02 2023-08-10 Novarock Biotherapeutics, Ltd. Antibodies against claudin-6 and uses thereof
IL310700A (en) * 2021-08-09 2024-04-01 Merck Patent Gmbh Proteins that uncouple cell-mediated tumor cytotoxicity from proinflammatory cytokine release
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
WO2024052445A1 (en) 2022-09-09 2024-03-14 Idorsia Pharmaceuticals Ltd Pharmaceutical combination comprising an anti-cd3 antibody and a cxcr3 antagonist

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US565332A (en) 1896-08-04 Toy for making soap-bubbles
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3546807C2 (pt) 1985-03-30 1991-03-28 Marc Genf/Geneve Ch Ballivet
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5763192A (en) 1986-11-20 1998-06-09 Ixsys, Incorporated Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ATE249840T1 (de) 1991-12-13 2003-10-15 Xoma Corp Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
EP1621554B2 (en) 1992-08-21 2012-08-29 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
JP2826272B2 (ja) 1993-10-26 1998-11-18 タイガースポリマー株式会社 中空樹脂成形品の製造装置及び製造方法
US5565352A (en) 1993-11-24 1996-10-15 Arch Development Corporation Deubiquitinating enzyme: compositions and methods
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
ES2288305T3 (es) * 1996-09-10 2008-01-01 Theodor-Kocher Institute Receptor de quimiocinas cxcr3, anticuerpos, acidos nucleicos y metodos de uso.
US6140064A (en) 1996-09-10 2000-10-31 Theodor-Kocher Institute Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
WO2001072334A2 (en) 2000-03-27 2001-10-04 Corixa Corporation Methods for treating disease with antibodies to cxcr3
AU2001298053A1 (en) 2001-09-27 2003-04-14 Pieris Proteolab Ag Muteins of apolipoprotein D
BRPI0411945A (pt) * 2003-06-30 2006-10-24 Bio Technology General Israel Anticorpos e seus usos
EP1631315B1 (en) 2003-09-24 2014-07-30 Millennium Pharmaceuticals, Inc. Antibodies which bind human cxcr3
WO2005094446A2 (en) * 2004-03-23 2005-10-13 Eli Lilly And Company Anti-myostatin antibodies
US20080181892A1 (en) 2004-08-11 2008-07-31 Trubion Pharmaceuticals Binding Domain Fusion Protein
WO2007121354A2 (en) 2006-04-14 2007-10-25 Trubion Pharmaceuticals Inc. Binding proteins comprising immunoglobulin hinge and fc regions having altered fc effector functions
AU2008210589B2 (en) * 2007-02-01 2013-09-19 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against CXCR3
NZ583605A (en) 2007-08-29 2012-10-26 Sanofi Aventis Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
US20100130476A1 (en) 2008-11-12 2010-05-27 The Scripps Research Institute Compounds that induce pancreatic beta-cell expansion
WO2010103517A1 (en) 2009-03-12 2010-09-16 Rappaport Family Institute For Research In The Medical Sciences Soluble compositions for the treatment of cxcr3-ligand associated diseases
HUE038313T2 (hu) * 2010-02-26 2018-10-29 Bioarctic Neuroscience Ab Protofibril-kötõ antitestek és alkalmazásuk Parkinson-kór, Lewy-testes demencia és más alfa-szinukleinopátiák terápiás és diagnosztikai eljárásaiban

Also Published As

Publication number Publication date
US20130251733A1 (en) 2013-09-26
CN104507967B (zh) 2018-10-12
MX359854B (es) 2018-10-12
LT2804878T (lt) 2018-12-10
JP2015506945A (ja) 2015-03-05
RS58141B1 (sr) 2019-02-28
UY34582A (es) 2013-09-02
JP6352812B2 (ja) 2018-07-04
EP2804878B1 (en) 2018-08-22
US20190119391A1 (en) 2019-04-25
WO2013109974A3 (en) 2013-11-07
TWI596112B (zh) 2017-08-21
US20140377806A1 (en) 2014-12-25
KR20200014441A (ko) 2020-02-10
JP6646100B2 (ja) 2020-02-14
CN104507967A (zh) 2015-04-08
SI2804878T1 (sl) 2018-12-31
MX2014008728A (es) 2015-07-06
JP2018166506A (ja) 2018-11-01
BR112014017814A2 (pt) 2017-06-20
PL2804878T3 (pl) 2019-03-29
AU2013209492B2 (en) 2018-02-08
US8865870B2 (en) 2014-10-21
ES2698606T3 (es) 2019-02-05
AU2013209492A1 (en) 2014-08-14
BR112014017814A8 (pt) 2017-07-11
CY1121335T1 (el) 2020-05-29
RU2663141C2 (ru) 2018-08-01
IL271697A (en) 2020-02-27
EP2804878A2 (en) 2014-11-26
RU2014134043A (ru) 2016-03-20
JP6352812B6 (ja) 2018-08-08
WO2013109974A2 (en) 2013-07-25
TW201335188A (zh) 2013-09-01
JP2020072715A (ja) 2020-05-14
IL233694A0 (en) 2014-09-30
DK2804878T3 (en) 2018-12-17
KR102073034B1 (ko) 2020-02-05
CA2862222A1 (en) 2013-07-25
HUE041900T2 (hu) 2019-06-28
SG10201700735PA (en) 2017-02-27
US20180086838A1 (en) 2018-03-29
AR090056A1 (es) 2014-10-15
HRP20181874T1 (hr) 2019-01-11
US9765144B2 (en) 2017-09-19
HK1208684A1 (en) 2016-03-11
KR20140116525A (ko) 2014-10-02
SG11201406762QA (en) 2014-11-27

Similar Documents

Publication Publication Date Title
IL285049A (en) Broad-spectrum neutralizing antibodies against the AIDS virus
IL271697A (en) Antibodies against CXCR3
IL264558A (en) Anti–il–23p19 antibodies
ZA201407509B (en) Anti-fcrn antibodies
HK1204571A1 (en) Protease-regulated antibodies
HK1210192A1 (en) Anti-siglec-15 antibodies siglec-15
EP2844290A4 (en) NOVEL ANTIBODIES
HK1210186A1 (en) Anti-h7cr antibodies h7cr
PL2935330T3 (pl) Przeciwciała przeciw notch3
EP2804876A4 (en) NEW ANTIBODIES
IL235188A0 (en) Antibodies against c-pdgf
GB201209584D0 (en) Modified antibodies